Abstract Background: Studies suggest that obesity is associated with lower risk of prostate cancer but more aggressive cancers. As lowers PSA levels, these observations may be influenced by detection bias. We examined the association between and low- high-grade in REDUCE, which biopsies were largely independent PSA. Methods: The REDUCE study tested dutasteride for reduction men a 2.5 to 10.0 ng/mL negative biopsy. Study participants included 6,729 who underwent at least one on-study baseline...

A recent meta-analysis showed that aspirin was associated with reduced prostate cancer risk. As anti-inflammatory medications lower PSA levels, whether these findings reflect detection or risk is unknown. We tested the association between and nonaspirin NSAID use on diagnosis in REDUCE, where all men received biopsies at 2 4 years largely independent of PSA. REDUCE dutasteride for reduction a 2.5 to 10.0 ng/mL negative prestudy biopsy.We examined aspirin, NSAIDs, both total, low-grade...

BACKGROUND The current study was performed to evaluate whether baseline acute and chronic prostate inflammation among men with an initial negative biopsy for cancer (PCa) increased the risk of subsequent PCa detection in a clinical trial systematic biopsies. METHODS A retrospective analysis 6238 aged 50 years 75 prostate‐specific antigen levels between 2.5 ng/mL 10 prior REduction by DUtasteride Events who completed 2‐year biopsy. PCa, inflammation, were assessed central review. association...

We evaluated associations between histological prostate inflammation, and the development progression of benign prostatic hyperplasia/lower urinary tract symptoms in men randomized to placebo REDUCE (Reduction by Dutasteride Prostate Cancer Events) study a 4-year period.The association acute chronic inflammation detected on baseline biopsies hyperplasia related parameters, including I-PSS (International Symptom Score) volume, at multiple time points during 4 years enrolled cancer prevention...

We examined the 4-year longitudinal association between histological prostate inflammation and chronic prostatitis/chronic pelvic pain syndrome. also studied development of new progressing existing syndrome in men randomized to placebo REDUCE (REduction by DUtasteride Cancer Events) population.At multiple time points during 4 years univariable multivariable analyses were performed acute detected on baseline biopsies incidence syndrome-like symptoms, defined as a positive response CPSI...

Objective To evaluate the relationship between number of metabolic syndrome ( MetS )‐like components and prostate cancer diagnosis in a group men where nearly all biopsies were taken independent prostate‐specific antigen PSA ) level, thus minimising any confounding from how various ‐like may influence levels. Subjects/Patients Methods We analysed data 6426 Reduction by Dutasteride Prostate Cancer Events REDUCE study with at least one on‐study biopsy. compared dutasteride vs placebo on risk...

Although the relationship between smoking and prostate cancer risk is inconsistent, some studies show that associated with mortality. Whether this reflects delayed diagnosis or direct smoking-related effects unknown. REDUCE, which followed biopsy-negative men protocol-dictated prostate-specific antigen (PSA)-independent biopsies at 2 4 years, provides an opportunity to evaluate minimal confounding from screening biases.Logistic regression was conducted test association on first on-study...

The role of metformin in prostate cancer chemoprevention remains unclear. REDUCE, which followed biopsy-negative men with protocol-dictated PSA-independent biopsies at 2- and 4-years, provides an opportunity to evaluate the link between use diagnosis minimal confounding from screening biases. In diabetic we tested association use, other antidiabetic medications, versus no medication as well grade (low-grade Gleason 4-6 high-grade 7-10) using logistic regression. Of 540 complete data, 205...

Abstract Both anti- and proinflammatory effects of cigarette smoking have been described. As prostate inflammation is common, we hypothesized could contribute to inflammation. Thus, evaluated the association status with acute chronic within men undergoing biopsy. We retrospectively analyzed 8,190 ages 50 75 years PSA levels between 2.5 10 ng/mL enrolled in Reduction by Dutasteride Prostate Cancer Events study. Smoking was self-defined as never, former, or current. assessed systematic central...

To what degree the associations between PCa risk and family history of prostate cancer (PCa) and/or breast (BCa) are attributable to screening biases is unclear. We examined these questions within REDUCE study, where biopsies were largely independent specific antigen (PSA) minimizing biases.Data from REDUCE, which tested dutasteride 0.5 mg daily for reduction in men with PSA 2.5-10.0 ng mL(-1) a negative prestudy biopsy. Among undergoing at least one on-study biopsy complete data (n = 6415;...

Abstract Statin use is associated with lower advanced prostate cancer risk. In addition to cholesterol lowering, statins have systemic anti-inflammatory properties. However, their effect on histologic inflammation not well understood, particularly among men at increased risk but a negative biopsy. We examined associations between serum lipid levels, statin use, and using data from 6,655 baseline biopsy in the REduction by DUtasteride of Cancer Events (REDUCE) trial. levels [total...

Although lower urinary tract symptoms and sleep problems often develop together, to our knowledge it is unknown whether disturbances are linked development progression. As measured by the 6-item MOS-Sleep (Medical Outcomes Study Sleep Scale) survey we examined relationship between problems, progression of in REDUCE (Reduction Dutasteride Prostate Cancer Events) study.REDUCE was a randomized trial testing prostate cancer chemoprevention with dutasteride men specific antigen 2.5 10 ng/ml...

To evaluate whether baseline acute and chronic prostate inflammation among men with initial negative biopsy for cancer (PC) is associated PC volume at the 2-year repeat in a clinical trial systematic biopsies.Retrospective analysis of 886 positive Reduction by Dutasteride Events (REDUCE) study. Acute tumor were determined central pathology. The association was evaluated linear Poisson regressions controlling demographics laboratory variables.Chronic, inflammation, both detected 531 (60%), 12...

Background T 2 ‐weighted imaging (T ‐WI) information has been used in a qualitative manner the assessment of prostate cancer. Quantitative derivatives relaxation time) can be generated from ‐WI. These outputs may useful helping to discriminate clinically significant cancer background signal. Purpose/Hypothesis To investigate changes quantitative parameters lesions and noncancerous tissue men on active surveillance for taking dutasteride 0.5 mg or placebo daily 6 months. Study Type...

No AccessJournal of UrologyAdult Urology1 Nov 2015Baseline Prostate Atrophy is Associated with Reduced Risk Cancer in Men Undergoing Repeat Biopsy Daniel M. Moreira, David G. Bostwick, Gerald L. Andriole, Bercedis Peterson, Harvey J. Cohen, Ramiro Castro-Santamaria, and Stephen Freedland MoreiraDaniel Moreira Department Urology, Mayo Clinic, Rochester, Minnesota More articles by this author , BostwickDavid Bostwick Laboratories, Inc., Glen Allen, Virginia Financial interest and/or other...

// Adriana C. Vidal 1 , Zinan Chen 2 Lauren E. Howard Daniel M. Moreira 3 Ramiro Castro-Santamaria 4 Gerald L. Andriole 5 Emanuela Taioli 6 Jay H. Fowke 7 Beatrice Knudsen 8 Charles G. Drake 9 J. Curtis Nickel 10 and Stephen Freedland Department of Surgery, Division Urology, Cedars Sinai Medical Center, Los Angeles, CA, USA Biostatistics Bioinformatics, Duke University School Medicine, Durham, NC, Mayo Clinic, Rochester, MN, GlaxoSmithKline Inc., R&D, King Prussia, PA, Washington...

To evaluate the association between acute and chronic inflammation with presence of perineural invasion (PNI) in prostate biopsies positive for cancer (PCa).We conducted a retrospective analysis 1 399 PCa Reduction by Dutasteride Events (REDUCE) study. PCa, PNI were assessed central pathology review. The was evaluated using chi-squared Kruskal-Wallis tests, logistic regression adjusting clinicopathological biochemical variables.The identified 133 (9.5%). In all, 267 (19.1%) had inflammation,...

Despite routine use of phosphodiesterase type 5 inhibitor to treat erectile dysfunction the role in prostate cancer chemoprevention remains unclear. Only a few studies have explored link between and cancer. We tested association risk REDUCE (Reduction by Dutasteride Prostate Cancer Events) trial.REDUCE was 4-year multicenter study testing effect daily dutasteride on men with specific antigen 2.5 10.0 ng/ml negative biopsy who underwent mandated biopsies at 2 4 years. The overall disease...

Abstract Background Batefenterol (BAT) is a bi-functional molecule with both muscarinic antagonist and β 2 -adrenoceptor agonist pharmacology. This Phase II, randomized, placebo-controlled, double-blind study evaluated the safety tolerability of BAT 300 μg fluticasone furoate (FF) 100 administered via ELLIPTA inhaler (BAT/FF 300/100). Methods Subjects stable chronic obstructive pulmonary disease were randomized 2:1 to receive BAT/FF 300/100 or placebo once daily for 6 weeks. The primary...